Critical care in the United Kingdom is now well-established in terms of professional status, standards of clinical practice and training, and national audit through professional bodies and government representation. Research is fundamental to the further development and maturation of the specialty, to develop new therapies and technologies, more efficient and effective service organisation, and to improve patient and family experience and outcomes. Critical care research has expanded rapidly in the UK, and now has established organisations and infrastructure to share and develop ideas, through the UK Critical Care Research Forum and similar meetings. In September 2014, the Intensive Care Foundation and Critical Care Leadership Forum hosted a research colloquium to reflect, in part, on achievements, but more importantly plan for the future. With an invited list of participants the meeting explored firstly -the practical delivery of clinical research and secondly -the future financing landscape, from both academic funders' and commercial developers' perspectives. The following article summarises the important 'take home' messages from this meeting and suggests key issues for future strategy.
of national research leaders, representing virtually all of the major government and charitable funders, attended and spoke. Senior members of the NIHR delivery network also contributed, along with leaders from industry and academic training programmes. These talks were complemented by presentations from members of the critical care community, reflecting on issues and opportunities specific to our specialty. The aim of this article is to report the key messages of these talks and discussions to the critical care community. We have used notes and discussions to summarise their impressions of the important 'take home' messages. We present suggested key learning points for moving forward.
What was said?
This report cannot capture in detail the content of all lectures, talks, and discussion. Table 1 lists the invited speakers from outwith critical care, their background, and the key messages we took from their talks and associated discussion.
A number of other contributions were made from members of the critical care community. Professor Tim Walsh (National Lead of the NIHR CRN: Critical Care Specialty) reflected on the impact of the NIHR clinical research network on critical care during the first 6 years of its existence. Great progress has been made, with increased numbers of studies, progressively increasing engagement of ICUs with embedded research staff and infrastructure, and a coordinating specialty group-based organisational structure that is improving access to and efficiency of research. Challenges for the future include maintaining activity through project grants, developing commercial/industry research, and coordinating allocation of new projects according to capacity and likely patient base. A move towards wider use of extended hours of screening and recruitment, including weekends, would likely have a major impact on recruitment. Dr Tony Gordon (ICS Co-director of research) reviewed the potential benefits of largescale international collaboration, and the need for large trials with sufficient statistical power to detect minimum clinically important differences in outcomes such as mortality. Given the heterogeneity of critical care populations, studies with power to detect important differences in a priori defined sub-groups is highly desirable. This is unlikely to be achieved within single countries, especially for specific types of critical care populations. Several projects have already explored the feasibility of international collaboration at different stages from planning through to post-funding participation. Success has been variable. Major challenges that have emerged include the timing and ability to satisfy multiple national funding bodies, and working to different timescales and review structures, potentially with differing research priorities. Sheila Harvey (CTU manager, ICNARC; www.icnarc.org) discussed recent experiences of optimising recruitment into critical care trials. She noted the importance of coordination and communication, and working closely with individual site teams and R&D departments. The NIHR network has offered significant benefits that can reduce the workload of trial management. The shared experience of the various trial units in recent years and multiple investigators with experience of setting up and delivering multicenter trials highlight the need to avoid 'silos' of expertise and to share knowledge and experience. At present we have no generic mechanism of sharing models of critical care research delivery, or core materials such as databases or questionnaires. Professor Gavin Perkins (Codirector of research, ICS) gave a brief overview of clinical trial activity and successes in the UK, highlighting the exponential growth in activity and key publications. Professor Danny McAuley (Co-director of research, ICS) highlighted the opportunities to develop and realise translational projects linking basic science discovery to clinical benefit. The NIHR schemes recognise this natural progression through its different Medical Research Council (MRC) and NIHR-funded schemes; the MRC contributes funding for the Efficacy and Mechanisms Evaluation programme, which acts as a bridge between basic and clinical research. However, the importance of only progressing to large and expensive phase III trials when both the science and the trial design are as fully worked out as possible is key to both success and value for money for funders. The history of negative trials in critical care highlights the importance of this issue. Dr Nazir Lone discussed the enormous potential for 'big data' to inform multiple aspects of knowledge about critical illness. In particular, these epidemiology approaches may enable better and more efficient trial design, for example through better stratification or adjustment, or for collecting longer term outcomes through data linkage methods. The need for high-quality research training in this area was clear.
Key messages
There were many messages for our specialty from this stimulating and collaborative meeting. The authors have attempted to refine these into some focused issues that may form the basis of future work, and serve to help prioritise where research effort should go. We have grouped these under several headings:
Clinical research question priorities 1. The community should develop research questions and submit these through the prioritisation schemes, with the aim of some projects being commissioned.
Research questions must have demonstrated clear
importance to the NHS: this may include the views of patients, clinicians, and other stakeholders but must demonstrate clear potential for costeffective improvements in care. 3. Research questions with global relevance that 'stretch' to the developing world are important to major funders (notably the Wellcome Trust) 4. Engage with major funders during research question development (especially the Wellcome Trust) 5. Research questions that involve or emerge from collaboration with Industry are a high priority: These could emerge at different developmental stages, ranging from pre-clinical basic science to early phase trials, and the design of phase III trials. 6. Infection and trauma are UK and global priorities relevant to critical care. which is still focused on experimental medicine, systems biology, and translational medicine. An increasing focus is on 'precision' medicine, involving a deeper understanding of disease processes and subtypes. There is recognition that research limited to animal models has not translated efficiently, and future work should increasingly utilize human models whenever feasible. Informatics and the use of 'big data' to better understand and model disease is key to the future. This may contribute to precision medicine by enabling treatments to be focused, or provide prediction tools. Informatics has major potential to increase efficiency and effectiveness of healthcare. Collaboration, especially with Engineering and Physical Sciences, is seen as the way to make major steps forward through novelty and maximizing cross-disciplinary knowledge and idea sharing. Avoidance of silos and or isolationalism both as a specialty and across specialties is vital. With this in mind it is important to be mutually supportive within a specialty, for example in relation to grant review. A key to future success within a specialty area is promoting and supporting academic training programmes, especially those that provide continuity and enable cross- Described the principles of the HTA and EME funding schemes, highlighting that there are commissioned and investigator-initiated schemes. Noted that commissioned schemes have undergone extensive review and prioritisation; these may be the major scheme going forward. Emphasised that investigator-initiated submissions require very strong evidence of importance to progress, and with funding cuts competition and prioritisation in this area would make this route challenging. Also noted that epidemiology and the use of 'big data' are likely to become themes through the HTA and HSDR programmes.
Develop important research questions, with strong justification, and submit as vignettes to be considered for commissioned calls.
Professor Sallie Lamb
Chair of HTA CET Board http://www.nets.nihr.ac.uk/ programmes/hta
Reflected on what makes a strong research question and a strong application. Noted the results of the James Lind Alliance Prioritisation exercise that was presented at the meeting, and emphasised that although these uncertainties have been developed in partnership with patients, it is vital that research questions are clearly feasible to answer, and also that these answers that will increase knowledge in a way that results in clinically and cost-effective changes to healthcare. Noted also the importance of investigator initiated proposals having detailed background and feasibility work in order to be competitive. This highlights the importance of epidemiology and use of data to inform the importance and design of projects. Discussed the need to develop efficient trial designs that offer better value for money Ensure the importance of research proposals is strongly justified at application stage. Ensure answering proposed research questions can be seen to lead to potential clinical and cost-effective improvements. Explore better methodology in trial and study design that is more efficient. The ABHI facilitates relationships between industry, government, and academic life science departments. Reiterated the perception that many Universities do not optimize this and need to develop relationships with industry in a more sophisticated way. Healthcare inventors and innovators need to move away from the philanthropic enthusiast model towards a more mature business approach from an early phase. This will maximize opportunity and success.
Dr Oliver Rausch
Access expert support and advice early during R&D activity, especially for innovations with commercial potential.
Dr Andrew Bayliff GSK A View from the pharmaceutical industry
Noted that most large pharma, including GSK, have therapeutic priority areas of relevance to critical care, such as infectious disease, immunity and inflammation, and respiratory disease. GSK specifically also note the limited transferability of data derived entirely from animal models. Noted that many pharmaceutical companies have anxiety about critical care based on history of failure and recognition that the heterogeneous nature of patient populations mitigate against successful studies based on syndromic inclusion criteria.
Pharma are interested in critical illness, but work to define phenotypes and knowledge to enable precision medicine are needed. Types of research 1. Research using 'big data' is a priority: In the UK, the acquisition of uniform ICU-level data through national audits offers enormous potential to use 'big data' in research, especially if linked to other data sets that provide additional information about co-morbidity and longer term outcomes. 2. Precision medicine approaches are needed for critical illness: The multiple sources of heterogeneity in critical care populations, including demographics, pre-illness morbidity, and acute illness type and severity could all contribute to variable effects, potentially in opposite directions, for similar interventions. Genetic variation could also influence these issues. In addition, the timing of an intervention may be important in a manner similar to the staging of cancer, but within a far more restricted time window. 3. Better genotyping and phenotyping of critical illness is needed: This will improve research quality on multiple levels. For example, for precision medicine a better understanding of clinical phenotypes and genotype may improve the timing and choice of intervention; this might involve biomarkers, other diagnostics, and patient pre-illness or acute illness characteristics. For trial design better methods of selecting trial participants, stratification or minimisation at randomisation, or adjustment in relation to outcome comparison could all improve trial efficiency and quality.
Professor Jim Neilson

4.
Research that involves or engages with the engineering and physical sciences is needed, for example using informatics to model 'big data', or novel technology for diagnostics: These collaborations have the potential to make major steps forward in understanding and treating disease. Breaking down academic silos to bring experience and knowledge together within and between institutions is needed. 5. Methodology research is needed: For example, to improve trial/study efficiency or to enable clinical and cost-effectiveness to be detected within heterogeneous populations. 6. International collaboration may be needed to achieve adequately powered studies: This requires work with funders to navigate simultaneous application, prioritization, and review processes. 7. Translational research, especially with Pharma and Technology industries, is a priority and is currently underdeveloped: Drivers for this include the need for Industry to access clinical data and academic expertise, and also the potential to attract research funding and IP to the UK. 8. Develop human models of disease processes wherever possible: The limited success of animal and cell-based work mean strategies to test novel therapeutics in human or 'humanised' models, for example isolated organs, healthy volunteers, or well-defined groups within ICU populations, should be considered at an early stage. The WT is reviewing and changing its career development schemes and fellowships, with the aim of being flexible and more inclusive of all disease areas. The WT is keen and encourages early-stage discussion of research ideas, and aims to have an open-door policy with specialties developing ideas for specific projects or programmes. Critical care have not used this opportunity to full effect, but it is common in other area. The WT is enthusiastic for establishing organised and targeted training fellowship schemes that have been developed with the strategic backing of specialty areas. Global health perspectives are very important, and are likely to continue. Projects that address questions with a global health context, which can be tested in laboratories or clinical pathways within the UK with knowledge transferrable into low and middle income countries, would be viewed favorably.
Develop specialty-level ideas with global relevance Discuss and engage with the WT at an early stage of development Develop training fellowship schemes with specialty-specific focus, but global relevance.
